319 related articles for article (PubMed ID: 17096474)
1. The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.
Gallant JE
AIDS Read; 2006 Oct; 16(10):556-9. PubMed ID: 17096474
[TBL] [Abstract][Full Text] [Related]
2. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
[TBL] [Abstract][Full Text] [Related]
3. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
Zaccarelli M; Perno CF; Forbici F; Cingolani A; Liuzzi G; Bertoli A; Trotta MP; Bellocchi MC; Di Giambenedetto S; Tozzi V; Gori C; D'Arrigo R; De Longis P; Noto P; Girardi E; De Luca A; Antinori A
Antivir Ther; 2003 Feb; 8(1):51-6. PubMed ID: 12713064
[TBL] [Abstract][Full Text] [Related]
4. Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine.
Cahn P; Wainberg MA
J Antimicrob Chemother; 2010 Feb; 65(2):213-7. PubMed ID: 20007333
[TBL] [Abstract][Full Text] [Related]
5. Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
Miller MD; Haddad M; Su C; Gibbs C; McColl DJ; Guyer B
Antivir Ther; 2012; 17(6):993-9. PubMed ID: 22837442
[TBL] [Abstract][Full Text] [Related]
6. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
7. Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.
McColl DJ; Margot N; Chen SS; Harris J; Borroto-Esoda K; Miller MD
HIV Clin Trials; 2011; 12(2):61-70. PubMed ID: 21498149
[TBL] [Abstract][Full Text] [Related]
8. Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.
Turner D; Brenner BG; Routy JP; Petrella M; Wainberg MA
New Microbiol; 2004 Apr; 27(2 Suppl 1):31-9. PubMed ID: 15646062
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.
Borroto-Esoda K; Parkin N; Miller MD
Antivir Chem Chemother; 2007; 18(5):297-300. PubMed ID: 18046962
[TBL] [Abstract][Full Text] [Related]
10. Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.
Aquaro S; Svicher V; Ceccherini-Silberstein F; Cenci A; Marcuccilli F; Giannella S; Marcon L; Caliò R; Balzarini J; Perno CF
J Antimicrob Chemother; 2005 Jun; 55(6):872-8. PubMed ID: 15845785
[TBL] [Abstract][Full Text] [Related]
11. Resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC) in HIV-1 isolated from paediatric patients.
Wainberg MA; Lewis L; Salomon H; Gu Z; Keller A; Cammack N; Goldsmith J; Church J; Spira B; Wheeler S; Pizzo P
Antivir Ther; 1996 Apr; 1(2):98-104. PubMed ID: 11321185
[TBL] [Abstract][Full Text] [Related]
12. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
von Wyl V; Ehteshami M; Symons J; Bürgisser P; Nijhuis M; Demeter LM; Yerly S; Böni J; Klimkait T; Schuurman R; Ledergerber B; Götte M; Günthard HF;
J Infect Dis; 2010 Apr; 201(7):1054-62. PubMed ID: 20170373
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.
Cahn P; Altclas J; Martins M; Losso M; Cassetti I; Cooper DA; Cox S
HIV Med; 2011 Jul; 12(6):334-42. PubMed ID: 21054750
[TBL] [Abstract][Full Text] [Related]
14. Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Svicher V; Alteri C; Artese A; Forbici F; Santoro MM; Schols D; Van Laethem K; Alcaro S; Costa G; Tommasi C; Zaccarelli M; Narciso P; Antinori A; Ceccherini-Silberstein F; Balzarini J; Perno CF
J Acquir Immune Defic Syndr; 2010 Nov; 55(3):336-44. PubMed ID: 20739898
[TBL] [Abstract][Full Text] [Related]
15. Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
Stirrup OT; Asboe D; Pozniak A; Sabin CA; Gilson R; Mackie NE; Tostevin A; Hill T; Dunn DT;
HIV Med; 2020 May; 21(5):309-321. PubMed ID: 31927793
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
Winters MA; Bosch RJ; Albrecht MA; Katzenstein DA;
J Infect Dis; 2003 Aug; 188(4):537-40. PubMed ID: 12898440
[TBL] [Abstract][Full Text] [Related]
17. The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro.
Drogan D; Rauch P; Hoffmann D; Walter H; Metzner KJ
Antiviral Res; 2010 Jun; 86(3):312-5. PubMed ID: 20302887
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
[TBL] [Abstract][Full Text] [Related]
19. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection.
Wainberg MA; Moisi D; Oliveira M; Toni TD; Brenner BG
J Antimicrob Chemother; 2011 Oct; 66(10):2346-9. PubMed ID: 21750100
[TBL] [Abstract][Full Text] [Related]
20. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
